兩連板模塑科技(000700.SZ):墨西哥工廠計劃今年3月份正式給特斯拉Model Y供貨
格隆匯1月8日丨模塑科技(000700.SZ)公佈,公司股票連續兩天漲停,經公司管理層自查,2019年6月份特斯拉將ModelY車型在北美市場的前後保險槓和門檻項目定點給模塑科技全資孫公司墨西哥名華Ming Huade Mexico,S.A.DEC.V.,Tesla要求預計產能18萬輛/年,具體實際訂單根據市場需求來定,項目週期從2020年開始五年時間。
墨西哥名華以聖路易斯波多西工廠作為生產中心,計劃2020年3月份正式供貨,目前特斯拉Model Y處於開發狀態。公司與特斯拉的合作將為公司全球化佈局奠定基礎,對公司未來年度的經營業績產生積極影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.